The National AIDS Treatment Advocacy Project - NATAP - provides the latest in HIV and AIDS drug research and treatment information as well as comprehensive reports and developments from the Fifth Retroviruses and Opportunistic Infections conference, as well as from the ICAR, ICAAC, IDSA, European and International HIV and AIDS conferences, and from other sources. 

HIGHLIGHTS FROM ICDCD:

• ICDCD Highlights, Report 1.
• ICDCD Highlights, Report 2.

DAILY HIGHLIGHTS FROM THE 4th INTERNATIONAL CONGRESS ON
DRUG THERAPY IN HIV INFECTION, GLASGOW, SCOTLAND:

• Pre-Conference Genotypic Resistance Test Seminar
• Report 1 from Glasgow
• Report 2 from Glasgow
• Report 3 from Glasgow
• Report 4 from Glasgow
• Report 5 from Glasgow
• Report 6 from Glasgow - The Final Report before returning to the Big Apple

A First Report in a Series on Resistance Testing; including a Geneva Report on Transmission of Protease Resistant Virus

DAILY HIGHLIGHTS FROM ICAAC:

Fifth Retroviruses & Opportunistic Infections Conference, Chicago, February 1-5, 1998

• Protease Inhibitor and Viral Load Strategy Update a ten-part report including reducing viral load to <50 copies/ml; Does rapid reduction of viral load promote durability?; In vitro cross-resistance: PIS and NRTIs; Paterns of Protease Inhibitor cross-resistance in 500 clinical isolates; Triple NRTI therapy during primary infection; SGC; Invirase vs Fortovase; and Fortovase vs Crixivan; Nelfinavir studies; 141W94; the potential for limiting or preventing PI cross-resistance by switching PIs immediately after viral load rebound (04/28/98)

• NRTI Report including comparisons of D4T/3TC vs AZT/3TC both with Indinavir; comparisions of D4T/DDI vs AZT/3TC both with Indinavir; 1592U89 Resistance and phenotypic testing; 1592 and Indinavir, Nelfinavir, SGC or 141W94, 2 drug combination; and New NRTI's in early development (04/28/98)

• PMPA (04/21/98)

• Early Combination Anitretroviral Therapy of Vertical HIV Infection - First Report on Viral Kinetics and Control of Viral Replication in Children (04/21/98)

• Lower Than Usual but Detectable Levels of Replication Competent Proviral DNA found in Individuals on HU/ddI/Indinavir (04/20/98)

• NNRTI update: Reports on Efavirenz (EFV); NNRTI Resistance; and Nevirapine (NVP) (04/12/98)

• Efavirenz (EFV) Reports includes PK effect of EFV on 141W94; 60 week data on EFV + Indinavir; 24 week data on EFV + AZT/3TC; and EFV CSF Levels in Monkeys (04/12/98)

• NNRTI Resistance Report (O4/12/98)

• 1592U89 (Abacavir) Expanded Access Program Announced (03/12/98)

• 1592 (Abacavir) Resistance and Phenotypic Resistance Testing (03/03/98)

Reports + Developments from ICAAC, IDSA, and Hamburg conferences

• Hydroxyurea (HU)

pdf

pdf

pdf

pdf

• Protease Inhibitors

• Double Protease combinations

• Nucleosides

• CSF and Anti-retroviral HIV Treatment

• Non-Nucleoside Treatment Information

• Other

Laboratories That Offer the Ultra-sensitive PCR Test to Individuals (1/21/98)

Salvage Therapy with 6 Drugs (1/21/98)

The Real Deal on the ICAAC Report by Steven Deeks of 53% Protease Inhibitors Failure Rate (1/21/98)

Impact of HAART on Opportunistic Infections (ICAAC) (1/21/98)

pdf

FIFTH RETROVIRUSES &
OPPORTUNISTIC INFECTIONS CONFERENCE
Chicago, February 1-5, 1998

• Protease Inhibitor and Viral Load Strategy Update a ten-part report including reducing viral load to <50 copies/ml; Does rapid reduction of viral load promote durability?; In vitro cross-resistance: PIS and NRTIs; Paterns of Protease Inhibitor cross-resistance in 500 clinical isolates; Triple NRTI therapy during primary infection; SGC; Invirase vs Fortovase; and Fortovase vs Crixivan; Nelfinavir studies; 141W94; the potential for limiting or preventing PI cross-resistance by switching PIs immediately after viral load rebound (04/28/98)

• NRTI Report including comparisons of D4T/3TC vs AZT/3TC both with Indinavir; comparisions of D4T/DDI vs AZT/3TC both with Indinavir; 1592U89 Resistance and phenotypic testing; 1592 and Indinavir, Nelfinavir, SGC or 141W94, 2 drug combination; and New NRTI's in early development (04/28/98)
• PMPA (04/21/98)
• Early Combination Anitretroviral Therapy of Vertical HIV Infection - First Report on Viral Kinetics and Control of Viral Replication in Children (04/21/98)
• A Report on HIV Detection by Viral Load and Culture in Semen (04/21/98)
• Immune Reconstitution - Responses of Follicular Dendritic Cells (FDC) to Antiretoviral Combination Therapy of HIV Infection in Lymphoid Tissues (04/20/98)
• Clearance of HIV Following 3, 4, or 5 drug combinations; and, trying to Maximize Viral Load Suppression with 5 drug Regimen (04/20/98)
• Lower Than Usual but Detectable Levels of Replication Competent Proviral DNA found in Individuals on HU/ddI/Indinavir (04/20/98)
• NNRTI update: Reports on Efavirenz (EFV); NNRTI Resistance; Nevirapine (NVP) (04/12/98)
• Reports on Efavirenz (EFV) includes PK effect of EFV on 141W94; 60 week data on EFV + Indinavir; 24 week data on EFV + AZT/3TC; and EFV CSF Levels in Monkeys (04/12/98)
• NNRTI Resistance Report (O4/12/98)
• Nevirapine (NVP) Report including 10 month study on NVP + d4T/3TC; NVP + D4T + NFV (Nelfinavir): preliminary interaction and antiviral activity data; Two year+ follow-up (INCAS) study of NVP + AZT/ddI;a 24 week study of  NVP+IDV=2 NRTIs;NVP + IDV + 3TC: 1 year follow-up in advanced HIV group (04/12/98)
• Preliminary Data on Protease BID Dosing Regimens: Nelfinavir and Indinavir (04/02/98)

• Double Protease Combinations (03/09/98) including: Ritonavir + Saquinavir; Nelfinavir + Saquinavir;  Indinavir + Nelfinavir; Ritonavir + Nelfinavir; 141+IDV, NFV, or SQV; and Commentary on Treating Protease Resistant Virus.

• 1592 (Abacavir) Resistance and Phenotypic Resistance Testing (03/03/98)